Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983 Jun;323(2):101-5.
doi: 10.1007/BF00634256.

Characterisation of postjunctional alpha-adrenoceptors in isolated human femoral veins and arteries

Characterisation of postjunctional alpha-adrenoceptors in isolated human femoral veins and arteries

E Glusa et al. Naunyn Schmiedebergs Arch Pharmacol. 1983 Jun.

Abstract

In order to characterise the pharmacological properties of postjunctional alpha-adrenoceptors, both the contractile effects of alpha-adrenoceptor agonists and the blocking potencies of selective alpha-adrenoceptor antagonists were studied in isolated human femoral veins and arteries. The veins were more sensitive to noradrenaline than the arteries. Guanfacine had a higher intrinsic activity in veins than in arteries, whereas the reverse was true for phenylephrine. The antagonists rauwolscine and yohimbine were more potent against noradrenaline in the veins than in arteries, while corynanthine was equally potent in either tissue. They antagonised the noradrenaline response in a competitive manner. Prazosin proved to be the most potent competitive antagonist in arteries, while in veins it exerted weak and non-competitive antagonism. The results suggest that the alpha-adrenoceptor population at the postjunctional site differs between human femoral veins and arteries. The veins seem to contain more alpha 2- than alpha 1-adrenoceptors postjunctionally, whereas in the arteries the alpha 1-subtype prevails. The results indicate the possibility of influencing selectively adrenergic reactions in the capacitance and resistance vessels.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Acta Pharmacol Toxicol (Copenh). 1978 Oct;43(4):291-8 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1979 Aug;308(2):127-36 - PubMed
    1. J Pharmacol Exp Ther. 1981 Nov;219(2):540-6 - PubMed
    1. Rev Physiol Biochem Pharmacol. 1981;88:199-236 - PubMed
    1. Br J Pharmacol Chemother. 1959 Mar;14(1):48-58 - PubMed

MeSH terms

Substances